Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5861-5865

  Kourounakis, Angeliki P ^a   Charitos, Christos ^b   Rekka, Eleni A ^c   Kourounakis, Panos N ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b ELPEN Pharmaceutical Co Inc   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 FLUOROPHENYL)PHENYL] 4 METHYLMORPHOLINYL 2 OL; 2 [4 (4 CHLOROPHENYL)PHENYL] 4 METHYLMORPHOLINYL 2 OL; 2 [4 (4 FLUOROPHENYL)PHENYL] 4 METHYLOCTAHYDRO 1,4 BENZOXAZIN 2 OL; 3 [4 (4 FLUOROPHENYL)PHENYL]OCTAHYDRO 1,4 PYRIDO[2,1 C]OXAZIN 3 OL; ANTILIPEMIC AGENT; AROMATIC COMPOUND; BIPHENYL DERIVATIVE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MORPHOLINE DERIVATIVE; OXAZINE DERIVATIVE; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HYPERLIPIDEMIA; IC 50; IN VIVO STUDY; LIPID PEROXIDATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; MAGNETIC RESONANCE SPECTROSCOPY; MICROSOMES, LIVER; MORPHOLINES; RATS; TRIGLYCERIDES;

EID: 52449105151     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800663w     Document Type: Article

References (33)

1. Stocker, R.; Keaney, J. F. Role of oxidative modifications in atherosclerosis. Physiology 2004, 84, 1381-1478.
2. Carpender, K. I.; Taylor, S. E.; Ballantine, J. A.; Fussell, B.; Halliwell, B.; Mitchinson, M. J. Lipids and oxidised lipids in human atheroma and normal aorta. Biochim. Biophys. Acta 1993, 1167, 121-130.
3. Brown, A. J.; Mander, E. L.; Gerissen, I. C.; Kritharides, L.; Dean, R. T.; Jessup, W. Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. J. Lipid Res. 2000, 41, 226-237.
4. Aronson, D. Inflammatory markers linking unstable plaques to coronary event, an international perspective. Int. J. Cardiovasc. Intervent. 2004, 6, 110-118.
5. Hansson, G. K. Inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. 2005, 352, 1685-1696.
6. Berliner, J. A.; Watson, A. D. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 2005, 353, 9-11.
7. Descamps-Latscha, B.; Witko-Sarsat, V.; Nguyen-Khoa, T.; Nguyen, A. T.; Gausson, V.; Mothu, N.; London, G. M.; Jungers, P. Advanced oxidation protein products as risk factors for atherosclerotic vascular events in nondiabetic predialysis patients. Am. J. Kidney Dis. 2005, 45, 39-47.
8. Tsimikas, S.; Witztum, J. L. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001, 103, 1930-1932.
9. Walley, T.; Folino-Gallo, P.; Stephens, P.; Van Ganse, E. EuroMedStat Group. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br. J. Clin. Pharmacol. 2005, 60, 543-551.
10. Amin, D.; Rutledge, R. Z.; Needle, S. N.; Galczenski, H. F.; Neuenschwander, K.; Scotese, A. C.; Maguire, M. P.; Bush, R. C.; Hele, D. J.; Bilder, G. E.; Perrone, M. H. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. 1997, 281, 746-752.
11. Ishihara, T.; Kakuta, H.; Moritani, H.; Ugawa, T.; Sakamoto, S.; Tsukamoto, S.; Yanagisawa, L. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg. Med. Chem. 2003, 11, 2403-2414.
12. Ishihara, T.; Kakuta, H.; Moritani, H.; Ugawa, T.; Sakamoto, S.; Tsukamoto, S.; Yanagisawa, L. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorg. Med. Chem. 2003, 11, 3735-3745.
13. Brown, G. R.; Clarke, D. S.; Foubister, A. J.; Freeman, S.; Harrison, P. J.; Johnson, M. C.; Mallion, K. B.; McCormick, J.; McTaggart, F.; Reid, A. C.; Smith, G. J.; Taylor, M. J. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J. Med. Chem. 1996, 39, 2971-2979.
14. Chrysselis, M. C.; Rekka, E. A.; Kourounakis, P. N. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J. Med. Chem. 2000, 43, 609-612.
15. Chrysselis, M. C.; Rekka, E. A.; Siskou, I. C.; Kourounakis, P. N. Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J. Med. Chem. 2002, 45, 5406-5409.
16. Tavridou, A.; Kaklamanis, L.; Megaritis, G.; Kourounakis, A. P.; Papalois, A.; Roukounas, D.; Rekka, E. A.; Kourounakis, P. N.; Charalambous, A.; Manolopoulos, V. G. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur. J. Pharmacol. 2006, 535, 34-42.
17. Tavridou, A.; Megaritis, G.; Kourounakis, A. P.; Charalambous, A.; Manolopoulos, V. G. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium 2007, 14, 239-243.
18. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A. P.; Rekka, E. A.; Kourounakis, P. N.; Charalambous, A.; Manolopoulos, V. G. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J. Pharmacol. Exp. Ther. 2007, 323, 794-804.
19. Hansch, C.; Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology; J. Wiley & Sons: New York, 1991.
20. Rankin, G. O.; Riley, T. N.; Murphy, J. C. 3-Aryl- and 3-Hydroxy-3-aryloctahydropyrido [2,1-c][1,4] Oxazines. Synthesis, Stereochemistry, and Central Nervous System Pharmacological Actions. J. Med. Chem. 1978, 21, 460-464.
21. Bettoni, G.; Franchini, C.; Perrone, R.; Tortorella, V. Synthesis and Absolute Configuration of Substituted Morpholins. Tetrahedron 1980, 36, 409-115.
22. Rekka, E.; Retsas, S.; Demopoulos, V. J.; Kourounakis, P. N. Lipophilicity of some morpholine derivatives synthesised as potential antinociceptive agents. Arch. Pharm. 1989, 323, 53-56.
23. Blicke, F. F.; Lu, C. H. Antispasmodics. XIX. Esters of 1-methyl-2-(hydroxymethyl)-pyrrolidine and 1-methyl-2-(hydroxymethyl)- piperidine. J. Am. Chem. Soc. 1955, 77, 29-31.
24. Sammes, M. P. The infrared spectrum of phthalocyanine: assignement of N-H Modes. J. Chem. Soc., Perkin Trans. 1972, 2, 158-159.
25. Bailey, T. R. Unsymmetrical Heterobiaryl Synthesis. A Highly Efficient Palladium-Catalyzed Cross-Coupling Reaction of HeteroarylTrialkylstannanes with Aryl Halides. Tetrahedron Lett. 1986, 27, 4407-1140.
26. Palmer, P. J.; Trigg, R. B.; Warrington, J. V. Antimicrobials. 3. Benzothiazolylphenylalkylamines. J. Med. Chem. 1971, 14, 1228-1230.
27. Mettey, Y.; Michaud, S.; Vierfond, J.-M. A synthesis of 2-substituted phenylbenzothiazoles. Heterocycles 1994, 38, 1001-1006.
28. Renoll, M. W. Vinyl Aromatic Compounds.Fluorinated Derivatives. J. Am. Chem. Soc. 1946, 68, 1159.
29. Lu, J.; Tao, Y.; D'Iorio, M.; Li, Y.; Ding, J.; Day, M. Pure Deep Blue Light-Emitting Diodes from Alternating Fluorene/Carbazole Copolymers by Using Suitable Hole-Blocking Materials. Macromolecules 2004, 37, 2442-2449.
30. Mowry, D. T.; Renoll, M.; Huber, W. F. Vinyl Aromatic Compounds. I. The Vapor Phase Dehydration of Arylmethylcarbinols. J. Am. Chem. Soc. 1946, 68, 1105-1107.
31. Matter, H.; Schudok, M.; Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Weithmann, K.; Wollmann, T. Tetrahydroisoquinoline-3- carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship. Bioorg. Med. Chem. 2002, 10, 3529-14.
32. Schwab, J. M.; Lin, D. C. T. Stereochemical Course of an Enzyme-Catalyzed Allene-Acetylene Isomerization. J. Am. Chem. Soc. 1985, 107, 6046-6052.
33. Amin, D.; Cornell, S. A.; Gustafson, S. K.; Needle, S. J.; Ullrich, J. W.; Bilder, G. E.; Perrone, M. H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res. 1992, 33, 1657-1663.